Effectiveness and tolerability of methylthioninium chloride (methylene blue) for the treatment of methemoglobinemia: twenty-four years of experience at a single poison center (2025)

Peer-Reviewed Study · Rothenberg R, Biary R, Hoffman RS · March 10, 2025

Rothenberg R et al., 2025-03-10: Twenty-four-year poison-centre series of 185 methylene-blue-treated methemoglobinemia cases: median dose 1 mg/kg, 98% improved, 4.9% had attributable adverse effects, and G6PD testing was done in only seven patients, two of whom were deficient.

Glucose-6-phosphate dehydrogenase activity was found to be deficient in two of seven patients tested, only one of whom did not improve after methylthioninium chloride.

Rothenberg R et al., 2025-03-10: Twenty-four-year poison-centre series of 185 methylene-blue-treated methemoglobinemia cases: median dose 1 mg/kg, 98% improved, 4.9% had attributable adverse effects, and G6PD testing was done in only seven patients, two of whom were deficient. C3 and C11. Dose/route: intravenous methylthioninium chloride, median 1 mg/kg (IQR 1-2, range 0.5-4); multiple doses in 11%, median total 2 mg/kg. Funder/conflicts not stated in abstract. Comparator: none. Bears on C3 in both directions: deficient patients appeared in the series without catastrophe, but testing was performed in only 7 of 185, so the series cannot measure G6PD risk. Also filed as MTO-67, MTI-18, MTF-30 (claims C11, C3, C6). Study type: uncontrolled series.